keyword
MENU ▼
Read by QxMD icon Read
search

EGFR inhibitor skin effect

keyword
https://www.readbyqxmd.com/read/28469331/differential-toxicities-of-tyrosine-kinase-inhibitors-in-the-management-of-metastatic-lung-cancer
#1
Karthik S Udupa, Rejiv Rajendranath, Tenali Sagar, Joseph Thomas
INTRODUCTION: Erlotinib and gefitinib are the most commonly used epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of EGFR mutant nonsmall cell lung cancer (NSCLC). Both erlotinib and gefitinib have shown equal efficacy in terms of response rates and overall survival. Hence, their toxicity profile becomes the most important determining factor in choosing these agents when treating EGFR mutant NSCLC. In this study, we compared the toxicity profile of erlotinib and gefitinib among an Indian subset of lung cancer patients...
January 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28464435/management-of-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-related-cutaneous-and-gastrointestinal-toxicities
#2
REVIEW
Derrick Chen-Wee Aw, Eng Huat Tan, Tan Min Chin, Hong Liang Lim, Haur Yueh Lee, Ross A Soo
Patients with advanced stage non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations using EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib and afatinib as first-line treatment had better progression-free survival, overall response rate and quality of life than those on chemotherapy. Although EGFR TKIs are commonly associated with skin-related (rash, xerosis and paronychia) and gastrointestinal-related (diarrhea and stomatitis) adverse events (AEs), these effects are usually mild...
May 2, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28456787/predictive-blood-plasma-biomarkers-for-egfr-inhibitor-induced-skin-rash
#3
Vivien Hichert, Catharina Scholl, Michael Steffens, Tanusree Paul, Christian Schumann, Stefan Rüdiger, Stefan Boeck, Volker Heinemann, Volker Kächele, Thomas Seufferlein, Julia Stingl
Epidermal growth factor receptor overexpression in human cancer can be effectively targeted by drugs acting as specific inhibitors of the receptor, like erlotinib, gefitinib, cetuximab and panitumumab. A common adverse effect is a typical papulopustular acneiform rash, whose occurrence and severity are positively correlated with overall survival in several cancer types. We studied molecules involved in epidermal growth factor receptor signaling which are quantifiable in plasma, with the aim of identifying biomarkers for the severity of rash...
April 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28442875/extreme-phenotype-of-epidermal-growth-factor-receptor-inhibitor-induced-destructive-folliculitis
#4
Florian Anzengruber, Barbara Meier, Julia-Tatjana Maul, Katrin Kerl, Lars E French, Alexander A Navarini
Due to the increasingly widespread use and side effect profile of epidermal growth factor receptor inhibitors (EGFRIs), cutaneous side effects of these drugs are frequently encountered. The EGFR is expressed on keratinocytes and fibroblasts. Inhibition of EGFR can produce a range of cutaneous adverse effects, the most frequent being a characteristic acneiform skin eruption. As the latter is associated with good anti-neoplastic responses, the onset of EGFRI-induced acneiform skin eruption is typically viewed as a positive sign by patients and physicians...
October 2016: International Journal of Trichology
https://www.readbyqxmd.com/read/28413391/minocycline-induced-hyperpigmentation-in-a-patient-treated-with-erlotinib-for-non-small-cell-lung-adenocarcinoma
#5
Ann T Bell, John W Roman, Max L Gratrix, Christina E Brzezniak
INTRODUCTION: While epidermal growth factor receptor (EGFR) inhibitors have improved progression-free survival in patients with non-small cell lung cancer (NSCLC), one of the most common adverse effects is papulopustular skin eruption, which is frequently severe enough to be treated with oral minocycline or doxycycline. CASE: We present a case of an 87-year-old man who developed a severe papulopustular skin eruption secondary to erlotinib therapy for NSCLC. Control of the eruption with 100 mg of minocycline twice daily for 8 months eventually led to blue-gray skin hyperpigmentation...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28299582/complete-tumor-response-with-afatinib-20%C3%A2-mg-daily-in-egfr-mutated-non-small-cell-lung-cancer-a-case-report
#6
Raffaele Giusti, Marco Mazzotta, Daniela Iacono, Salvatore Lauro, Paolo Marchetti
Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is efficacious as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Dosage reduction is recommended in patients with intolerable adverse events; however, data regarding the efficacy of low-dose afatinib are limited. We report the case of a 71-year-old female patient who was diagnosed with advanced EGFR-mutated NSCLC and started treatment with oral afatinib 40 mg daily. The patient achieved partial tumor response on computed tomography imaging, but developed unacceptable skin-related toxicities requiring dosage reduction to 20 mg daily...
June 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28120452/silibinin-treatment-inhibits-the-growth-of-hedgehog-inhibitor-resistant-basal-cell-carcinoma-cells-via-targeting-egfr-mapk-akt-and-hedgehog-signaling
#7
Arpit Dheeraj, Cynthia M Rigby, Cindy L O'Bryant, Chapla Agarwal, Rana P Singh, Gagan Deep, Rajesh Agarwal
Basal cell carcinoma (BCC) is the most common skin malignancy. Deregulated hedgehog signaling plays a central role in BCC development; therefore, hedgehog inhibitors have been approved to treat locally advanced or metastatic BCC. However, the development of resistance to hedgehog inhibitors is the major challenge in effective treatment of this disease. Herein, we evaluated the efficacy of a natural agent silibinin to overcome resistance with hedgehog inhibitors (Sant-1 and GDC-0449) in BCC cells. Silibinin (25-100 μm) treatment for 48 h strongly inhibited growth and induced death in ASZ001, Sant-1-resistant (ASZ001-Sant-1) and GDC-0449-resistant (ASZ001-GDC-0449) BCC cells...
January 25, 2017: Photochemistry and Photobiology
https://www.readbyqxmd.com/read/28004308/cutaneous-side-effects-and-transepidermal-water-loss-to-gefitinib-a-study-of-11-patients
#8
Franky Chandra, Dendi Sandiono, Unwati Sugiri, Oki Suwarsa, Hendra Gunawan
INTRODUCTION: Cutaneous side effects caused by epidermal growth factor receptor (EGFR) inhibitors occurred in 45-100% of patients which may lead to therapy modification or interruption. This study aimed to evaluate cutaneous side effects and transepidermal water loss (TEWL) values in non-small cell lung carcinoma (NSCLC) patients who received gefitinib EGFR inhibitor. METHODS: A descriptive observational study with cross-sectional design and a consecutive sampling method was conducted from 1 February to 4 March 2016...
March 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/27893423/efficacy-and-safety-of-icotinib-in-treating-non-small-cell-lung-cancer-a-systematic-evaluation-and-meta-analysis-based-on-15-studies
#9
Rong Biaoxue, Liu Hua, Gao Wenlong, Yang Shuanying
Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China; this work was to evaluate its efficacy and safety in treating non-small cell lung cancer (NSCLC). Clinical studies evaluating the efficacy and safety of icotinib in treating NSCLC were identified from the databases of Medline, Web of Science, Embase and Cochrance Library. Pooled efficacy and safety of icotinib were calculated through a series of predefined search strategies. A total of 15 studies with 2,304 patients were involved in this study...
December 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/27833902/minocycline-improves-the-efficacy-of-egfr-inhibitor-therapy-a-hypothesis
#10
Ajit Venniyoor, Bassim Al Bahrani
Skin rash is a side effect of drugs that inhibit epithelial growth factor receptor (EGFR) as a part of targeted therapy of cancer. Its appearance and severity correlates with survival. Minocycline, an oral tetracycline antibiotic, is recommended as treatment (and increasingly, for prevention) of the rash, though infection is seen in only one-third of the patients. Minocycline has additional anticancer properties such as poly(ADP-ribose) polymerase inhibition. It is proposed that such properties contribute to the efficacy of EGFR inhibitors and can also explain the positive correlation between grade of rash and survival as patients with higher grades of rash are more likely to receive minocycline...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27791234/cutaneous-toxicity-from-epidermal-growth-factor-receptor-inhibitors-would-a-subcutaneous-desensitization-be-helpful-case-report
#11
Andrea D'Alessio, Sara Cecchini, Daniela Di Mauro, Luca Geroli, Simonetta Villa, Antonello Quadri, Davide Resta, Carmelo Fortugno
PURPOSE: Cetuximab and panitumumab are monoclonal antibody inhibitors that bind the epidermal growth factor receptor (EGFR) currently used in the treatment of metastatic colorectal cancer. The main adverse event related to EGFR inhibitors (EGFR-Is) is cutaneous toxicity, which can cause dosage reduction and interruption of treatment. State-of-the-art management of skin toxicity associated with EGFR-Is therapy involves the topical administration of corticosteroids and oral antibiotics, but is not completely effective in the management of toxicity...
November 11, 2016: Tumori
https://www.readbyqxmd.com/read/27766784/retrospective-study-of-adjuvant-icotinib-in-postoperative-lung-cancer-patients-harboring-epidermal-growth-factor-receptor-mutations
#12
Shuyang Yao, Xiuyi Zhi, Ruotian Wang, Kun Qian, Mu Hu, Yi Zhang
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations occur in about 50% of Asian patients with non-small cell lung cancer (NSCLC). Patients with advanced NSCLC and EGFR mutations derive clinical benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs). This study assessed the efficacy and safety of adjuvant icotinib without chemotherapy in EGFR-mutated NSCLC patients undergoing resection of stage IB-IIIA. METHODS: Our retrospective study enrolled 20 patients treated with icotinib as adjuvant therapy...
September 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27755795/lung-squamous-cell-carcinoma-with-brachial-soft-tissue-metastasis-responsive-to-gefitinib-report-of-a-rare-case
#13
Kana Kataoka, Eiji Osaka, Tetsuo Shimizu, Yuki Okamura, Yukihiro Yoshida, Yasuaki Tokuhashi
Metastasis of lung cancer to soft tissue is rare and patient outcomes are generally poor. There are no reports describing soft tissue metastasis in lung squamous cell carcinoma (SCC), in which gefitinib treatment was effective not only for the primary tumor but also the metastatic lesion. A 61-year-old Asian woman presented to our facility with pain and a mass in the brachium. An additional tumor was identified in the lung. As we suspected soft tissue metastasis of lung cancer, an incisional biopsy was performed, yielding a diagnosis of SCC...
November 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27725919/afatinib-associated-cutaneous-toxicity-a-correlation-of-severe-skin-reaction-with-dramatic-tumor-response-in-a-woman-with-exon-19-deletion-positive-non-small-cell-lung-cancer
#14
Lindsay P Osborn, Philip R Cohen
Epidermal growth factor receptor (EGFR) inhibitors are biological factors used in the treatment of non-small-cell lung cancers (NSCLC) that are positive for EGFR mutations. Afatinib is one such drug that has been approved for use in this capacity. Cutaneous toxicity is the second most commonly reported adverse event with the use of afatinib. A 39-year-old woman with inoperative right lung adenocarcinoma was initially treated with afatinib. She not only developed a severe papulopustular eruption but also had a dramatic reduction of her tumor...
September 1, 2016: Curēus
https://www.readbyqxmd.com/read/27720938/identification-of-gene-expression-profiling-associated-with-erlotinib-related-skin-toxicity-in-pancreatic-adenocarcinoma-patients
#15
Octavio Caba, Antonio Irigoyen, Cristina Jimenez-Luna, Manuel Benavides, Francisco M Ortuño, Javier Gallego, Ignacio Rojas, Carmen Guillen-Ponce, Carolina Torres, Enrique Aranda, Jose Prados
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that showed activity against pancreatic ductal adenocarcinoma (PDAC). The drug's most frequently reported side effect as a result of EGFR inhibition is skin rash (SR), a symptom which has been associated with a better therapeutic response to the drug. Gene expression profiling can be used as a tool to predict which patients will develop this important cutaneous manifestation. The aim of the present study was to identify which genes may influence the appearance of SR in PDAC patients...
October 6, 2016: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/27680009/-cutaneous-squamous-cell-carcinoma
#16
REVIEW
U Leiter, R Gutzmer, M Alter, C Ulrich, A S Lonsdorf, M M Sachse, U Hillen
Squamous cell carcinoma (SCC) of the skin accounts for 20 % of non-melanoma skin cancer and is one of the most frequent types of cancer in Caucasian populations. Diagnosis is based on the clinical features and should be histopathologically confirmed to adequately address the prognosis and treatment. Complete surgical excision with histopathological control of excision margins is the gold standard in the treatment of primary SCC. Sentinel lymph node biopsies (SLNB) can be considered in SCC with a tumor thickness of >6 mm but there is currently no evidence concerning prognostic and therapeutic effects...
November 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27668532/anti-proliferation-effects-efficacy-of-cyasterone-in-vitro-and-in-vivo-and-its-mechanism
#17
XinGang Lu, HongFu Qiu, Liu Yang, JieYing Zhang, ShuJie Ma, Lan Zhen
Cyasterone was demonstrated potential inhibition effect in mouse skin carcinoma cells in published report. However, the molecular mechanisms of the cyasterone on cells remain unknown. Herein, we investigated the effects of cyasterone-induced apoptosis in A549 and MGC823 cells in vitro. MTT assay showed that cyasterone caused a significantly decreasing of the proliferation of A549 and MGC823 cells in a time-and dose-dependent manner with IC50 values of 38.50±3.73μg/mL on A549 cells and 32.96±1.24μg/mL on MGC823 cells at 48h, respectively...
December 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27641462/-osimertinib-tagrisso-%C3%A2-activity-indication-and-modality-of-use-in-non-small-cell-lung-cancer
#18
Etienne Giroux Leprieur, Alexis B Cortot, Jacques Cadranel, Marie Wislez
The acquisition of a resistance EGFR mutation in exon 20 (T790M) occurs in half of the cases of secondary resistance to EGFR tyrosine kinase inhibitors (TKI), given in first-line treatment in advanced EGFR-mutated non-small cell lung cancers (NSCLC). Osimertinib (AZD9291, Tagrisso(®)) is a third-generation, irreversible EGFR TKI, active in case of T790M mutation. A large phase I trial showed the efficacy of osimertinib after failure of first-generation EGFR TKI (erlotinib, gefitinib), with response rate at 51% and up to 61% in case of T790M mutation...
October 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27630354/appetite-loss-as-an-adverse-effect-during-treatment-with-egfr-tkis-in-elderly-patients-with-non-small-cell-lung-cancer
#19
Minehiko Inomata, Kazuki Shimokawa, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Toru Yamada, Toshiro Miwa, Ryuji Hayashi, Tatsuhiko Kashii, Shoko Matsui, Kazuyuki Tobe
AIM: We conducted a retrospective study to investigate the frequency of appetite loss during treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in elderly patients, aged 75 years or older, with non-small cell lung cancer harboring EGFR gene mutations. PATIENTS AND METHODS: Data of a total of 64 patients, including 39 relatively young (hereinafter, younger) patients and 25 elderly patients were analyzed. RESULTS: Appetite loss of all grades (p=0...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27565916/successful-oral-desensitization-against-skin-rash-induced-by-alectinib-in-a-patient-with-anaplastic-lymphoma-kinase-positive-lung-adenocarcinoma-a-case-report
#20
Masayuki Shirasawa, Masaru Kubotaa, Shinya Harada, Hideyuki Niwa, Seiichiro Kusuhara, Masashi Kasajima, Yasuhiro Hiyoshi, Mikiko Ishihara, Satoshi Igawa, Noriyuki Masuda
Alectinib has been approved for the treatment of patients with anaplastic lymphoma kinase (ALK) gene rearrangement-positive advanced non-small cell lung cancer. In terms of adverse effects, the occurrence of a severe skin rash induced by alectinib is reportedly rare, compared with the occurrence of skin rash induced by epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). In the present case report, a 76-year-old woman with ALK-positive lung adenocarcinoma experienced disease progression after undergoing first-line chemotherapy...
September 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
keyword
keyword
47998
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"